Skip to content

Effect of Simiaosan on Inflammatory Factors and Uric Acid Levels in Gout Patients with Damp-Heat Blockage Syndrome

Effect of Simiaosan on Inflammatory Factors and Uric Acid Levels in Gout Patients with Damp-Heat Blockage Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000227
Enrollment
Unknown
Registered
2024-08-13
Start date
2021-12-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

B:Provide treatment with Simiao San
A:Oral administration of Erecoxib tablets

Sponsors

Quzhou Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Both are consistent with the diagnostic criteria of traditional Chinese medicine and Western medicine for gout. Acute gout patients admitted to our hospital are classified as damp heat block type based on syndrome differentiation, and confirmed by clinical examination (urate crystals were found through polarized light microscopy and other examinations); (2) Not receiving any other form of treatment recently (within 4 weeks); (3) Vital signs are in a stable state (such as blood pressure, heart rate, etc.); (4) The serum uric acid (UA) level is greater than 10.0mg/dl. (5) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) concomitant osteomyelitis, rheumatoid arthritis, and purulent arthritis; (2) Combining malignant tumors and mental illnesses; (3) Merge hematopoietic, endocrine, or liver and kidney dysfunction; (4) Allergies or contraindications to the medication used in this article; (5) Women who are currently pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Traditional Chinese Medicine Syndrome Points;Serum uric acid;Pain level digital rating scale;

Secondary

MeasureTime frame
Interleukin-6;sICAM-1;Hypersensitive C-reactive protein;

Countries

china

Contacts

Public Contactshaowenfei

Quzhou Hospital of Traditional Chinese Medicine

13750703711@163.com15695703711

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026